secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001171843-24-004482
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q2 net income $5.1M on warrant revaluation; HERALD topline due early Q4
------------------------------------------------------------------------------

- Cash $94.5M at June 30, down from $135.7M year-end; runway through end of 2025.
- Net income of $5.1M ($0.03/sh) vs net loss of $18.8M (-$0.43) YoY; non-cash warrant income $30.5M.
- R&D spend $21.1M (+26% YoY) on clinical trial costs; G&A $6.4M (-30% YoY).
- ALG-055009 (MASH) HERALD enrollment complete; topline data expected early Q4 2024.
- ALG-000184 (CHB) showed sustained HBV DNA suppression in 90-100% of subjects; FDA supports registration endpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184324004482/0001171843-24-004482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184324004482/f8k_080624.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-004482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer